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Ralph M. Steinman
The infection of cultured monocyte-derived dendritic cells (DCs) with HIV-1 involves CD4 and CCR5 receptors, while transmis-
sion to T cells is enhanced at least in part by the lectin DC-SIGN/CD209. In the present study, we studied BDCA-1 myeloid DCs
isolated directly from human blood. These cells express CD4 and low levels of CCR5 and CXCR4 coreceptors, but not DC-SIGN.
The myeloid DCs replicate two R5 viruses, BaL and YU2, and transfer infection to activated T cells. The virus productively infects
a small fraction of the blood DCs that fail to mature in culture, as indicated by the maturation markers CD83 and DC-LAMP/
CD208, and the expression of high CD86 and MHC class II, in contrast to many noninfected DCs. A greater proportion of
BDCA-1 DCs are infected when the virus is pseudotyped with the vesicular stomatitis envelope VSV-G (5–15%), as compared
with the R5 virus (0.3–3.5%), indicating that HIV-1 coreceptors may limit the susceptibility of DCs to become infected, or the
endocytic route of viral entry used by HIV/vesicular stomatitis virus enhances infectivity. When infected and noninfected cells are
purified by cell sorting, the former uniformly express HIV p24 gag and are virtually inactive as stimulators of the allogeneic MLR,
in contrast to potent stimulation by noninfected DCs from the same cultures. These results point to two roles for a small fraction
of blood DCs in HIV-1 pathogenesis: to support productive infection and to evade the direct induction of T cell-mediated
immunity. The Journal of Immunology, 2006, 176: 991–998.
D endritic cells (DCs)
3 represent 1–2% of the mononuclear
leukocytes in human blood, and comprise at least two
major subsets that are distinguished by their reactivity
with a panel of monoclonal bodies as well as their function (1–4).
The myeloid DC subset is BDCA 1 and CD11c, while plasma-
cytoid DCs (PDCs) are CD123 and CD11c. These two popu-
lations of DCs are reduced in the blood of HIV-1-infected patients
suggesting that DCs are being targeted by HIV-1 infection (5–8),
possibly at an immature developmental stage. To better understand
HIV pathogenesis, the consequences of the interaction of HIV with
blood DCs need further study.
In contrast, it is amply demonstrated that a fraction of immature
monocyte-derived DCs (9–14) and Langerhans cells (15–17) can
be productively infected with HIV-1. In addition these DCs, in the
absence of overt infection, can transfer HIV-1 to receptor-positive
T cells (10, 14–19). In monocyte-derived DCs, which are DCs that
are differentiated from monocytes in culture by addition of GM-
CSF and IL-4, the lectin DC-SIGN/CD209 is one receptor that
allows the cells to sequester virus for transmission to T cells (20–
24), which takes place at a virologic synapse (25, 26). Importantly,
the infection of monocyte-derived DCs does not lead to maturation
and in fact blocks maturation to a panel of stimuli (27). This prop-
erty of the infected cells would lead to immune evasion, because
it is the mature form of DC that is a powerful inducer of immunity
to its captured and presented Ags, while immature DCs can induce
tolerance (28–31).
In contrast to the ease with which monocyte-derived DCs can be
obtained for research, blood DCs are relatively few in number and
difficult to isolate in a homogenous form. Conflicting reports exists
on the extent to which bulk populations of blood DCs can be
infected with HIV (11, 32, 33). Nevertheless, both myeloid and
plasmacytoid DCs express the requisite receptors for HIV-1 entry,
i.e., CD4, CCR5, and CXCR4 (11, 32). With respect to transmis-
sion of HIV-1 from blood DCs to T cells, one study reported that
this might take place and be mediated by DC-SIGN (33), but DC-
SIGN expression has been difficult to detect on freshly isolated
myeloid DCs (2, 11). In this study, we take advantage of the
BDCA-1 Ab to rapidly purify myeloid DCs from human blood and
study the ability of these cells to replicate HIV-1, and to spread
virus to T cells. We will show that HIV-1 preferentially infects a
small fraction of freshly isolated myeloid DCs, particularly when
HIV particles pseudotyped with vesicular stomatitis envelope
(VSV-G) are used. Surprisingly, the infected DCs do not mature
and exhibit very weak immunostimulatory functions.
Materials and Methods
DC isolation
DCs were isolated from the blood of normal donors, usually starting from
buffy coats purchased from the New York Blood Center. Myeloid or con-
ventional DCs were obtained from Ficoll-Hypaque-enriched mononuclear
cells using the BDCA-1 isolation kit (Miltenyi Biotec). The DCs were
routinely phenotyped to determine contamination with CD3-, CD19-,
CD16-expressing cells. The preparations contained 0.05–1% CD3 T
cells and only traces of CD19 and CD16 cells. PDCs were obtained
using the BDCA-4 isolation kit (Miltenyi Biotec). The enriched prepara-
tions were 75% CD123, with most of the contaminants being CD19 B
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cells. Monocyte-derived DCs were prepared as described (34) with mod-
ification. Briefly, CD14 cells were obtained using anti-CD14 Miltenyi
beads and cultured for 6 days with IL-4 (10 ng/ml; R&D Systems) and
GM-CSF (100 IU/ml; Immunex). The culture medium was RPMI 1640
supplemented with 5% AB human serum (Gemini Bio-Products).
Cell surface markers of myeloid DCs
Freshly prepared DCs were phenotyped with mAbs all directly conjugated
with PE and purchased from BD Pharmingen. In some experiments, the
DCs were cultured for 24–48 h with IL-4 at 10 ng/ml before the FACS
staining to induce the expression of DC-SIGN/CD209. The DCs were also
phenotyped for HIV-1 receptors expression using anti-CD4 PE, anti-
CXCR4 PE, and anti-CCR5 FITC (BD Pharmingen).
Infection of myeloid DCs with HIV-1
Purified, pelleted HIV-1 BaL (R5, stock at 50% tissue culture-infective
dose (TCID50) of 10
7.7/ml) and HIV-1 III B (X4, stock at a TCID50 of
108/ml) were obtained from Advanced Biotechnologies. We were provided
with YU2/GFP plasmid from M. Muesing (Aaron Diamond AIDS Re-
search Center, New York, NY) and viral particles were prepared by trans-
fection of 293 T cells. After 50 h, supernatants were collected and titered
for HIV p24 gag protein. We also produced HIV-1/VSV particles by co-
transfecting 293 cells with VSV-G and HIV minus envelope plasmids ex-
pressing GFP and titrated these as described (35). We infected cells at a
dose of 2 ng of p24 gag/105 cells. A total of 2  105 cells were infected
for 2 h in round-bottom wells, washed four times and transferred to new
wells. In some cases, AZT (National Institutes of Health AIDS Reagent
Program) at 1 M was added to the culture 20 min before infection and
then kept throughout the experiment to inhibit the viral life cycle.
Detection of HIV-1 in infected myeloid DCs and in DC-T cell
cocultures
To assess direct infection of DCs by HIV-1 BaL, cells were collected at
several time points, fixed, and permeabilized (Cytofix/Cytoperm reagents;
BD Pharmingen) and double-stained with FITC anti-HIV gag p24 (clone
KC 57; Beckman Coulter) and CD11c PE, DC-LAMP/CD208 PE (Immu-
notech), the latter to define DCs that had undergone maturation (36). For
cells infected with viruses expressing GFP, in general, the staining was
without permeabilization. Samples were analyzed on a FACSort (BD
Pharmingen) with CellQuest software. To assess transmission of virus to
activated T cells, the DCs were infected with HIV-1 for 2 h, washed, and
transferred to a new tube. After 4 h, cells were counted and 5  104 DCs
were cocultured with 105 T blasts in round-bottom wells in 200 l of
medium. In some experiments, T blasts were added 48 h after the infection
of the myeloid DCs. These steps were designed to remove free virions that
could infect T blasts directly. Supernatants were collected and infection
monitored at several time points by an ELISA for HIV gag p24 release
(Beckman Coulter). Alternatively, infection was measured by FACS stain-
ing for p24 gag Ab.
Chemotaxis assays
Purified myeloid DCs, 2  105 in 100 l of complete medium, were added
to Transwell chambers (24-well, 5-m pore size; Corning) with 600 l of
medium in the lower chamber, with or without chemokines. Stromal cell-
derived factor-1 (SDF-1)/CXCL12 and MIP-1/CCL3 (R&D Systems)
were added at concentrations ranging from 10 to 1000 ng/ml. After 3 h of
incubation at 37°C, the Transwell insert was removed. The cells in the
lower chamber were collected and enumerated by collecting events for a
fixed time (60 s) on a FACSCalibur.
Immunostimulatory function of cells infected with HIV/VSV
Myeloid DCs were infected with HIV/VSV and after 5 days were sorted as
GFP positive (infected cells) or GFP negative (noninfected cells). To fur-
ther verify that the GFP cells were infected, sorted GFP-positive and
negative myeloid DC were attached to printed slides (Carlson Scientific)
coated with polylysine (Sigma-Aldrich) and left to adhere at 37°C for 30
min in serum-free medium. The cells were washed, fixed, permeabilized,
and stained with anti-HIV gag p24 and HLA-DR for 45 min at room tem-
perature followed by goat anti-mouse IgG Alexa 546 at a dilution of 1/800
(Molecular Probes). As a control, matching isotype IgG was applied to
samples. Fluorescence was examined with a model AX70 Olympus laser
scanning microscope. To assess immunostimulatory function, the sorted
GFP and GFP DCs were added in graded doses to 105 allogeneic T cells
that had been labeled with CFSE. The MLR was assessed by CFSE dilution
at days 4–8.
Results
Cell surface markers of isolated myeloid DCs
We verified that BDCA-1-purified myeloid DCs, freshly isolated
from blood, expressed several typical DC markers including high
levels of CD11c and HLA-DR (Fig. 1A). Most cells expressed
moderate levels of CD86 and DEC-205/CD205 (Fig. 1A). A vari-
able frequency of the DCs stained weakly for CD83 (Fig. 1A) or
DC-LAMP/CD208 (data not shown), ranging from 10 to 40% of
the BDCA-1 fraction. BDCA-1-selected DCs were negative for
DC-SIGN/CD209, MMR/CD206, and CCR7 (Fig. 1A). When the
cells were cultured for 24 h without (Fig. 1B) or with (data not
shown) CD40L-expressing cells, there were small increases in
CD83, CD86, and HLA-DR (Fig. 1B, upper row). However,
CD206 and CD209 were both strongly induced during 24 h of
culture in IL-4 (Fig. 1B, lower row). The DCs expressed CD4,
CCR5, and CXCR4, i.e., the requisite receptors and coreceptors for
HIV-1 (Fig. 1C). The CXCR4 and CCR5 receptors were func-
tional, as assessed in a chemotaxis assay. Cells migrate in response
to their respective ligands, SDF-1/CXCL12 for CXCR4 and
RANTES (CCL5), MIP-1 (CCL3) and  (CCL4) for CCR5 (Fig.
1D). These data indicate that myeloid DCs in fresh human blood
should be susceptible to HIV-1, and also that the cells only acquire
the MMR and DC-SIGN markers of monocyte-derived DCs fol-
lowing culture in IL-4.
Productive infection of myeloid DCs by HIV
We next assessed HIV-1 infection using R5 and X4 viruses that
use CCR5 and CXCR4 coreceptors, respectively. The production
of p24 was analyzed at the single-cell level by FACS. With R5
viruses, positive cells started to be detected by the third day after
infection and peaked at 5 days (Fig. 2A). At later time points, the
DC preparation had poor viability. A very small fraction of the
freshly isolated DCs showed p24 staining after exposure to X4
virus. At most, 0.1% of the cells stained for IIIB p24 3–5 days later
(data not shown), whereas 0.3–3.5% of the cells were positive for
BaL p24 (Fig. 2A). If the infected cultures were simultaneously
stained for HIV-1 p24 and DC maturation markers, DC-LAMP/
CD208 (Fig. 2A), CD83 (Fig. 2B), or CD86 and MHC II (data not
shown here, but see Fig. 5A below), the low expressing or less
mature cells were preferentially infected. No p24 cells were de-
tected when the reverse transcriptase inhibitor AZT was added
before infection, indicating that p24 expression represented viral
replication within DCs (Fig. 2B, lower panels). The few contam-
inating resting T in the culture cells did not become gag positive
upon HIV-1 infection (Fig. 2C).
The infection of DCs with GFP virus was further characterized
to rule out that the staining seen by FACS was a consequence of
autofluorescence. To this end, after 4–5 days of viral infection,
cells were sorted as GFP and GFP and stained for expression of
gag p24 and HLA-DR. As expected, all the GFP cells stained
diffusely for gag p24 (Fig. 2D, top left). Interestingly, the cells
replicating virus showed an immature phenotype with a punctuate
HLA-DR staining mostly localized in intracellular vesicles (Fig.
2D, bottom left). These data indicate that a subset of myeloid DCs
can be infected with HIV-1. Infection selects for the more imma-
ture cells, and does not mature the susceptible BDCA-1 cells.
HIV-1-infected myeloid DCs transmit virus to T cells
To assess the capacity of myeloid DCs to transmit HIV-1 to T
cells, we exposed the DCs for 2 h to either of two R5 isolates, BaL
and YU2, the latter expressing GFP. The DCs were washed thor-
oughly and were added to CD4 T cells immediately or after 2
days of infection. When HIV-1 p24 production was analyzed by
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ELISA, infection could be detected to a similar extent when the
cocultures were started at day 0 (Fig. 3, experiment 1) or at 48 h
after DC infection (Fig. 3, experiment 2). To verify that most of the
infection was occurring in the T cells, we used YU2-GFP virus and
double-labeled for CD3 (Fig. 3B). This FACS approach showed
that CD3high, CD11cdim T cells expressed GFP at a level of 2–7%
of the T cells depending on individual experiments (of nine per-
formed). There was little or no spread of infection to DCs in the
DC-T coculture, because there were few infected CD11chigh cells
in the FACS plots (Fig. 3B). These results indicate that myeloid
DCs are capable of transmitting virus preferentially to T cells.
Comparison of virus transmission by DC subsets
To assess the efficiency of different types of DCs to transmit HIV
to T cells, monocyte-derived DCs were compared with the two
major subsets of blood DCs, all prepared from the blood of the
same individual and infected with HIV-1 BaL in parallel. Consis-
tently in five experiments, the monocyte-derived DCs were supe-
rior in their ability to transmit infection with R5 virus to T cells
(Fig. 3C). In one other set of experiments, we compared the ca-
pacity of myeloid DCs and PDCs to be infected and spread R5 and
X4 virus to activated T cells. The results indicated that the R5 virus
was transmitted more efficiently then X4 virus by myeloid DCs to
T cells, while the percentage of T blasts infected after exposure of
PDC to R5 or X4 viruses was quite similar (data not shown). In the
absence of T cells, we quantitated the amount of gag p24 released
in the culture supernatants of the infected DCs by ELISA. After 5
days of infection, 106 monocyte-derived DCs released between 0.5
and 2 ng of p24 while myeloid DC released 0.1–0.8 ng of p24.
Infection of myeloid DCs with VSV-pseudotyped virus
HIV-1 particles can be pseudotyped by envelope glycoproteins
such as VSV glycoprotein VSV-G. The VSV envelope mediates
efficient entry into DCs, but only a single cycle of replication is
possible because the progeny viral genomes lack an envelope. We
have previously shown, using VSV-G-pseudotyped HIV-1 parti-
cles, that monocyte-derived DCs permit a single cycle of viral
replication, and that the pseudotyped HIV-1 enters the cell through
a pH-sensitive pathway (35), independently from the classic HIV-1
pathway that is mediated by CD4 and either the CCR5 or CXCR4
coreceptors. Thus, the use of VSV/HIV-1 allows one to study the
replication potential of myeloid DCs without the restriction of
HIV-1 receptor expression. In fact, the percentage of cells infected
with VSV/HIV-1 was significantly higher, ranging from 5 to 14%
as compared with HIV-1 BaL (range 0.3–3.5%, Fig. 4). These
results indicate that the intrinsic ability of DCs to replicate virus is
greater than is evident with standard infection protocols. The ex-
pression of HIV-1 coreceptors in myeloid DCs may limit their
susceptibility to be infected or VSV envelope may enhance
infection.
Effects of maturation stimuli on HIV-1 replication on myeloid
DCs
We have shown, using monocyte-derived DC, that an exogenous
maturation stimulus added to DC abrogates viral replication and
also that infection itself does not drive maturation (27). We now
show that analogous results can be obtained when blood DCs are
matured by several maturation stimuli. Freshly prepared myeloid
DCs were infected with HIV-1 and exposed to maturation stimuli
at various times after infection. A total of 0.3–3% of the DCs in
FIGURE 1. Expression of surface Ags and HIV-1 receptors in myeloid DCs (MyDCs). A, Purified MyDCs were stained immediately with mAbs and
analyzed by FACS. B, Purified MyDCs were cultured for 24 h with or without 10 ng/ml IL-4. Cells were analyzed by FACS for the indicated markers.
C, Freshly purified MyDCs and PDCs were analyzed for the expression of CD4, CCR5, and CXCR4 (black line). The gray lines represent staining with
isotype-matched control Ab. D, The capacity of MyDCs to migrate in response to SDF-1 (CXCL12) or RANTES (CCL5), MIP-1 (CCL3), and MIP-1
(CCL4) was assessed in a chemotaxis assay.
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culture were GFP positive, when the DCs were infected with
YU2GFP HIV in the absence of maturation stimuli (Fig. 5A, top
row), but if maturation stimuli were added 1 day after infection
(we tested poly I:C and R848, which are TLR3 and TLR7/8 li-
gands, respectively, as well as a mixture of inflammatory cyto-
kines, IL-1, IL-6, and TNF-), no infected cells were detected 3
days later in six separate experiments, as illustrated in Fig. 5A,
middle row. If the addition of maturation stimuli was delayed 3
days, and then the stimuli added for 1–2 days, the yield of the
infected cells was again reduced as shown in Fig. 5A, lower panel.
We then repeated the experiments with VSV/HIV. In the absence
of maturation stimuli, the infected cells showed always an imma-
ture phenotype, with low CD86 and DC-LAMP as shown in Fig.
5B. When we added maturation stimuli at day 3, as shown in the
lower part of Fig. 5B, most of the infected DCs 2 days later re-
mained immature with low expression of CD86 and DC-LAMP.
The reliability of this observation is summarized for several ex-
periments in Table I. We verified that the cultured infected cells
had markers of DCs, e.g., CD11chigh, HLA-DR and CD86 posi-
tive, and CD3 negative. Therefore, maturation stimuli shut off viral
replication when added early in the viral life cycle, and when
added later on (3 days), the productively infected cells remain in an
immature state in terms of surface markers (see also Fig. 2D)
FIGURE 2. Productive HIV-1 infection of myeloid DCs. A, DCs were
infected (BaL) or not infected for 2 h. The cells were washed and cultured
for 5 days. Permeabilized cells were double-labeled for infection with anti-
p24 FITC (infected cells are circled) and for other DC markers, either
PE-labeled isotype control Ig, anti-CD11C, or anti-DC-LAMP PE. B, My-
eloid DCs were pretreated or not with 1 M AZT and then infected with
YU2/GFP. After 5 days, cells were stained with anti-CD11c PE or anti-
CD83 PE (surface staining) to phenotype the infected GFP-positive cells
(circle). C, DCs were infected with YU2/GFP and stained with the indi-
cated surface markers. Note that the few CD3 contaminating resting T cells
were not infected. D, Myeloid DCs were infected with HIV/GFP for 4
days. Cells were sorted as GFP positive and negative and stained for p24
gag and HLA-DR. Some punctuate stain in the infected GFP-negative frac-
tion is probably the result of internalized virions. This pattern is not present
in the noninfected cells.
FIGURE 3. HIV-1-infected DCs transmit infection to T cells. A, My-
DCs were pulsed with BaL or YU2/GFP for 2 h, washed, and cocultured
with activated T cells. T blasts were added immediately to the virus-pulsed
DCs (exp 1) or 48 h after the DC infection (exp 2). p24 release into the
supernatants was quantified by ELISA. B, DCs were pulsed with YU2/GFP
for 2 h, washed, and T blasts added after 48 h. Cultures were collected at
5 days, stained with either anti-CD3 allophycocyanin or anti-CD11c allo-
phycocyanin, and analyzed by FACS. C, Efficiency of HIV transmission by
different types of DCs. Immature monocyte-derived DCs (obtained after 6
days of culture) and freshly isolated blood myeloid and plasmacytoid DC
were infected with BaL for 2 h, washed, and cultured for 48 h. The different
DCs were then cocultured with T blasts and the kinetics of p24 release into
the supernatants were measured by ELISA.
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Blood DCs purified according to BDCA1 expression show het-
erogeneity being 50% CD14 and 50% CD14 . To assess viral
replication in these subsets, the BDCA1-selected DCs were
sorted as CD14 and CD14 and studied for their susceptibility to
infection with or without maturation. As seen in Fig. 5C, both
CD14-positive and -negative myDCs were susceptible to HIV-1
replication, and again maturation of DC decreased viral
replication.
HIV-1-infected blood DCs exhibit weak stimulatory function in
the MLR
Because of the substantial frequency of infected cells with VSV-
pseudotyped HIV, we were able to separate infected from nonin-
fected myeloid DCs using VSV/HIV-pseudotyped GFP virus. Af-
ter 5 days of infection, cells were sorted as GFP (infected) and as
GFP (not infected). These sorted cells were assessed for their
stimulatory activity in an allogeneic MLR over a range of DC to T
cell ratios and time points. The MLR was monitored using CFSE-
labeled responder cells. The GFP noninfected cells induced a
strong MLR, with a peak of CFSElow T cells developing in just 4
days of the MLR, and at low DC to T cell ratios (Fig. 6). In
contrast, the GFP cells were virtually nonstimulatory (Fig. 6).
We also verified that the infected DCs did not suppress the induc-
tion of T cell proliferation by the noninfected DCs even when a
10-fold excess of the infected DCs was added to the coculture of
the noninfected cells (Fig. 6C). The infected DCs were further
compromised in their capacity to secrete the immunostimulatory
cytokine IL-12p70. Although 106 GFP cells upon maturation re-
leased 278 pg of IL-12 p70, the infected DCs failed to produce this
cytokine. IL-10 was undetectable. Addition of neutralizing anti-
IL-10 Abs to the MLR with HIV-1-infected DCs did not restore T
cell proliferation (data not shown). These results provide func-
tional evidence that the interaction of HIV with myeloid DCs se-
lects for less immunostimulatory forms of DCs and/or blocks the
functional maturation of these cells.
Discussion
A large body of work has been directed to understanding the role
of DCs as an early site of HIV-1 infection and as a driving force
for subsequent CD4 T cell infection. However, the study of DCs
that are present in human blood, as opposed to the more accessible
monocyte-derived cultured DCs, has been compromised by the
fact that the cells are difficult to isolate. Nonetheless, there is clear
evidence with new mAbs that mark DCs and their subsets (37) that
the two populations of blood DCs, myeloid and plasmacytoid, are
significantly reduced in number during HIV-1 infection when
compared with normal individuals (5–8). Not only the percentage
of DCs decreases with the progression of the disease but also their
FIGURE 5. Effect of maturation stimuli
added to HIV-1-infected myeloid DC. My-
eloid DCs were infected with HIV/GFP.
Maturation stimuli were added at the indi-
cated time postinfection. After 5 days, cells
were analyzed by FACS for expression of
GFP and the maturation marker. A, Infec-
tion with YU2/GFP and detection of sur-
face Ags after maturation with cytokine
mixture. B, Infection with HIV/VSV and
detection of DC-LAMP and CD86 in per-
meabilized cells after maturation with R
848 at 1 M. C, BDCA 1 cells were
sorted as CD14 and CD14 infected with
HIV/GFP and after 2 days part of the cul-
tures were matured with R 848 at 1 M and
Poly I:C at 25 g/ml. After 5 days, cells
were analyzed for GFP expression.
FIGURE 4. Infection of myeloid DC by HIV particles pseudotyped with
VSV-G. DCs were infected with HIV-1/VSV or YU2/GFP. Productively
infected cells were studied for the expression of GFP by FACS 5 days later.
Table I. Failure of HIV-1-infected myeloid DC to maturea
Experiment Maturation Marker % Mature GFP % Mature GFP
1 high CD86 54 4.8
DC-LAMP 58 3.2
2 high CD86 27 0.2
DC-LAMP 31 0.7
3 high CD86 71 1.4
DC-LAMP 54 1.2
4 DC-LAMP 54 0
5 DC-LAMP 50 0.36
a BDCA-1 blood DCs were infected with IIIV/VSV for 3 days, and then matured
for 2 days with R848 (I M) and poly I:C (30 g/ml). At day 5, cells were perme-
abilized and stained with CD86 and the DC maturation marker DC-LAMP. The fre-
quency of GFP and GFP cells expressing high CD86 or DC-LAMP, as in Fig. 5,
are shown.
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function as APCs seems reduced (5–7). Using bulk cultures of
myeloid DC and PDC, it has been shown that these populations
can be infected with HIV-1 (11, 32). The availability of mAbs to
specific Ags expressed on DC subsets (37) facilitates their isola-
tion and allows one to perform more detailed studies in highly
enriched populations. Except for a recent study by Lore et al. (38),
prior research has not considered the two major subsets of DCs
purified by these efficient new isolation methods.
In this study, we show that myeloid DCs express CD4 and func-
tional chemokine receptors CXCR4 and CCR5, which are known
receptors required for HIV infection. Our studies, performed at the
single-cell level, show that R5 HIV-1 replicates in myeloid DCs
and that replication is blocked by the reverse transcriptase inhibitor
AZT indicating productive infection. However, the percentage of
productively infected myeloid DCs is low, in the range of 0.3–
3.5%. X4 HIV-1 also seems to replicate within rare cells in this DC
population. Nonetheless, a low level of infected DCs may be suf-
ficient to facilitate virus transmission to T cells, in view of the fact
that one DC can sample a large number of T cells (39, 40). Al-
though the frequency of infection of blood myeloid DCs is low, it
is possible that an immediate progenitor of the blood DC, e.g., in
the bone marrow, is much more susceptible to infection and ac-
counts for the reduction of DCs observed in the blood of HIV-1-
infected individuals.
Blood DCs are able to transfer a productive infection to T cells,
although we find that they are less efficient than the more fre-
quently studied monocyte-derived DCs. Several factors may be
involved in this effect. Monocyte-derived DCs have several virus
attachment factors (41) that may not be present in myeloid DCs or
PDCs from blood. Moreover, several C-type lectins, among them
DC-SIGN, are highly expressed in monocyte-derived DCs (20, 42)
and may function in enhancing infectivity by concentrating viral
particles at the virological synapse (25, 26, 43).
Using HIV-1 virions that had been pseudotyped with the
VSV-G envelope protein, we were able to increase the proportion
of infected myeloid, BDCA-1 DCs. The infection rate ranged
from 0.3 to 3% for R5 virus to 5%, even up to 15%, for VSV
HIV. VSV pseudotyping virus bypasses the CD4/CCR5 pathway
used by the R5 envelope and instead infects the DCs via acidic
compartments (35). Our results indicate that viral receptors are
somehow regulating replication of R5 virus in myeloid DCs, or
that the VSV-G envelope enhances infection.
As in our recent studies with monocyte-derived DCs, we find
that HIV primarily infects cells that are less mature in phenotype
(27). By simultaneously labeling the infected cells with Abs to p24
gag protein, we found that the p24 cells predominantly expressed
lower levels of the CD86 costimulator and MHC class II Ag-pre-
senting products. Even after 3–4 days of culture, little or no CD83
or DC-LAMP, two markers of DC maturation, were detectable.
When we sorted the infected DCs from noninfected DCs, using
VSV-pseudotyped GFP-expressing virus, we observed that the in-
fected cells were in addition functionally immature, being al-
most inactive as stimulators of the MLR. Decreased stimulation
FIGURE 6. Infected myeloid DCs are weak stimulators in the MLR. Myeloid DCs were infected with HIV/VSV and sorted after 5 days as GFP and
GFP. Sorted DCs were then added in graded doses to 105 allogeneic CFSE-labeled CD3 T cells (DC:T cell ratios are indicated). At several time points,
the presence of an MLR was documented by CFSE dilution. Shown here are two typical experiments of four performed (A and B). In C, GFP cells were
cocultured with GFP cells and CFSE-labeled allogeneic T cells. The MLR was documented after 8 days.
996 DCs AND HIV-1 INFECTION
of T cell proliferation was also reported when the enriched pop-
ulation of HIV-1-infected monocyte-derived DC were used as
stimulators in a MLR (44). These data point to a new evasion
strategy of HIV-1, whereby infected cells will be poor direct
stimulators of T cell-mediated immunity. Instead, the induction
of immunity would require cross-presentation of HIV-1 Ags
within dying infected cells, most likely T cells, by uninfected
DCs, a possibility that has been documented by Buseyne et al.
(45) and Larsson et al. (46).
At this time, our data do not distinguish between two possibil-
ities. HIV-1 may select for a subset of DCs that is resistant to
maturation, or as we suspect, HIV-1 itself blocks the maturation of
the cells that are infected. In either case, our findings imply that
presentation of HIV-1 Ag by infected blood DCs can lead to tol-
erance, a newly recognized property of immature DCs within lym-
phoid tissues (28–31). Taken together, the results in this paper
indicate that HIV-1 exploits the myeloid DCs in blood not only for
replication and transmission, but also for immune evasion.
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